Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies

被引：0

作者：

Stefanie Förderreuther

Qi Zhang

Virginia L. Stauffer

Sheena K. Aurora

Miguel J. A. Láinez

机构：

[1] Ludwig Maximilian University,Department of Neurology

[2] Sanofi,undefined

[3] Eli Lilly and Company,undefined

[4] Lilly Corporate Center,undefined

[5] Hospital Clínico Universitario,undefined

[6] Universidad Católica de Valencia,undefined

来源：

The Journal of Headache and Pain | 2018年 / 19卷

关键词：

Galcanezumab; Migraine; Preventive; Persistence; Maintenance;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[41] A phase 3 placebo-controlled study of galcanezumab in patients with chronic migraine: results from the 3-month double-blind treatment phase of the REGAIN study
Detke, Holland C.
Wang, Shufang
Skljarevski, Vladimir
Ahl, Jonna
Millen, Brian A.
Aurora, Sheena K.
Yang, Jyun Yan
JOURNAL OF HEADACHE AND PAIN, 2017, 18
[42] Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab
Ayer, David W.
Skljarevski, Vladimir
Ford, Janet H.
Nyhuis, Allen W.
Lipton, Richard B.
Aurora, Sheena K.
HEADACHE, 2018, 58 (08): : 1225 - 1235
[43] Effect of Fremanezumab on the Total Burden of Migraine in Patients with Episodic or Chronic Migraine: Findings from 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies
Sun-Edelstein, Christina
Cohen, Joshua M.
Gandhi, Sanjay K.
Barash, Steve
Brandes, Jan Lewis
NEUROLOGY, 2021, 96 (15)
[44] Onset of Migraine Preventive Effects With Rimegepant in a Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Trial
Lipton, R. B.
Kudrow, D.
Smith, T.
Croop, R.
Jensen, C. M.
Kamen, L.
Thiry, A.
Coric, V.
Goadsby, P. J.
JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 18 - 19
[45] Onset of Migraine Preventive Effects With Rimegepant in a Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Trial
Lipton, R. B.
Kudrow, D.
Smith, T.
Croop, R.
Jensen, C. M.
Kamen, L.
Thiry, A.
Coric, V.
Goadsby, P. J.
CEPHALALGIA, 2021, 41 (1_SUPPL) : 27 - 28
[46] Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)
Ford, Janet
Tassorelli, Cristina
Leroux, Elizabeth
Wang, Shufang
Ayer, David
Nichols, Russell
Detke, Holland
QUALITY OF LIFE RESEARCH, 2021, 30 (01) : 105 - 115
[47] Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)
Janet Ford
Cristina Tassorelli
Elizabeth Leroux
Shufang Wang
David Ayer
Russell Nichols
Holland Detke
Quality of Life Research, 2021, 30 : 105 - 115
[48] Impact of Fremanezumab on Disability Severity in Patients With Episodic and Chronic Migraine: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies
Nagy, Abraham J.
McAllister, Peter
Cohen, Joshua M.
Ning, Xiaoping
Campos, Verena Ramirez
Du, Evelyn
Ashina, Messoud
NEUROLOGY, 2021, 96 (15)
[49] IMPACT OF FREMANEZUMAB ON DISABILITY SEVERITY IN PATIENTS WITH EPISODIC AND CHRONIC MIGRAINE: POOLED RESULTS OF 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDIES
Nagy, Abraham J.
McAllister, Peter
Cohen, Joshua M.
Ning, Xiaoping
Campos, Verena Ramirez
Du, Evelyn
Ashina, Messoud
CEPHALALGIA, 2020, 40 : 93 - 94
[50] CHANGES IN PATIENT FUNCTIONING AND DISABILITY IN A PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL EVALUATING GALCANEZUMAB FOR CHRONIC MIGRAINE PREVENTION (REGAIN)
Ford, J. H.
Detke, H. C.
Ayer, D.
Wang, S.
Tockhorn-Heidenreich, A.
Nichols, R. M.
CEPHALALGIA, 2018, 38 : 55 - 55

← 1 2 3 4 5 →